CTDH - CTD Holdings, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1800
-0.0050 (-2.70%)
At close: 1:07PM EDT
Stock chart is not supported by your current browser
Previous Close0.1850
Open0.1900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1800 - 0.1930
52 Week Range0.1600 - 1.1800
Volume69,075
Avg. Volume90,538
Market Cap21.786M
Beta (3Y Monthly)0.94
PE Ratio (TTM)N/A
EPS (TTM)-0.0590
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE

    Why Did Board Insiders Recently Buy More Than 500,000 Shares of This Company's Stock?

    ORLANDO, FL / ACCESSWIRE / September 17, 2019 / Florida-based biopharma CTD Holdings (CTDH) saw a wave of insider buying from its board members over the last several weeks. Over a 45-day period, the company's board members purchased more than 500,000 shares of CTDH common stock in the open market, with 90% of the shares purchased by independent, outside directors. The timing of the latest purchases followed the company's announcements earlier in July 2019 regarding the treatment of an Alzheimer's patient with its drug candidate for more than a year under an FDA compassionate use program, and the Company's endorsement of Alzheimer's Disease as its next drug development indication.

  • Business Wire

    CTD Holdings Announces FDA Approval of US Expanded Access Treatment Program in Niemann-Pick Disease Type C

    CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the company will provide Trappsol® Cyclo™, its proprietary hydroxypropyl beta cyclodextrin drug, to a pediatric patient diagnosed with Niemann-Pick Disease Type C. The company received notice today of the FDA approval of the individual IND application from the treating physician, Caroline Hastings, MD, pediatric hematologist/oncologist at the UCSF Benioff Children’s Hospital in Oakland, CA. CTD’s Chairman and CEO, N. Scott Fine, said, “CTD was the first to provide cyclodextrins for use in NPC patients on an expanded access basis in the United States, this was in 2009.

  • Business Wire

    CTD Holdings to Present at 2019 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom

    CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the company will present on its clinical and drug development program for the orphan drug, Trappsol® Cyclo™, at the Niemann-Pick UK (NPUK) 10th Interactive Workshop on Niemann-Pick Diseases and the 26th Annual NPUK Family Conference. The conference brings together patients, families, caregivers, scientists, and health professionals for the purposes of learning about advances in NPC clinical trials and providing opportunities for community learning, sharing and support.

  • Business Wire

    CTD Holdings Interview to Air on Bloomberg International on the RedChip Money Report

    CTD Holdings, Inc. (CTDH), a clinical stage biopharmaceutical company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today an interview with Company Chair and CEO N. Scott Fine will air on The RedChip Money Report television program. The interview will air Sunday, September 8, on Bloomberg International, available in 149 million homes across Europe, the Middle East, and Africa. In the exclusive interview, Fine discusses the Company’s use of Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, which is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease, on a compassionate use basis as well as in three ongoing formal clinical trials, and the company’s plans to begin a development program targeting Alzheimer’s Disease.

  • Business Wire

    CTD Holdings Holds Shareholders’ Meeting: All Proposals are Approved

    CTD Holdings, Inc. (CTDH), a clinical stage biopharmaceutical company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that it held a meeting of shareholders in New York City for the purpose of approving three proposals, all of which were approved by a wide margin. Granting the Board of Directors authority to effect a reverse split of shares. The name change to Cyclo Therapeutics, Inc. will be implemented in the next few weeks following FINRA approval.

  • Business Wire

    CTD Announces New Data Presented at Annual Gathering of Patients and Families Tackling Niemann-Pick Disease Type C

    CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today posted its presentation to be made at the annual Family Support and Medical Conference organized by the National Niemann-Pick Disease Foundation (NNPDF). The company’s presentation to families will be made on August 16, followed by a Q & A session.

  • Business Wire

    CTD Holdings Announces Filing of Data From Expanded Access Program in Late Onset Alzheimer’s Disease in Support of Its Patent Application Filed In 2018

    CTD Holdings, Inc. (CTDH), a clinical stage biopharmaceutical company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that it has filed supporting data for its patent application titled “Methods for Treating Alzheimer’s Disease.” The original patent application was filed October 29, 2018 for the use of hydroxypropyl beta cyclodextrins in the treatment of Alzheimer’s Disease. According to the US Centers for Disease Control and Prevention, there were 5.7 million Americans living with Alzheimer’s Disease in 2018. “The data filed with the US Patent and Trademark Office are from a single patient suffering from Alzheimer’s Disease who has been intravenously using Trappsol® Cyclo™, our proprietary hydroxypropyl beta cyclodextrin, for one year,” said N. Scott Fine, CTD’s Chairman and CEO.

  • GlobeNewswire

    CTD Holdings Submits Application for Listing on NASDAQ

    ALACHUA, FL, June 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it has submitted its application to list its common stock on the NASDAQ Capital Market. The Company’s management has completed the application and submitted the request to list on The Nasdaq Capital Market. "We are excited to take this next step in the maturation of our company," said N. Scott Fine, CTD's Chairman of the Board and CEO.

  • ACCESSWIRE

    CTD Announces Continuation of Expanded Access Program in Single Alzheimer's Patient

    ALACHUA, FL / ACCESSWIRE / June 10, 2019 / CTD Holdings, Inc. (CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the annual report on "Expanded Access to Trappsol® Cyclo™ for an Individual Patient with Late-Onset Alzheimer's Disease" has been received by FDA according to investigator-sponsor Diana R. Kerwin, MD, President, Kerwin Research Center, allowing the company to continue to support the program.

  • ACCESSWIRE

    CTD Holdings Closes $7.4 Million Private Placement

    ALACHUA, FL / ACCESSWIRE / May 31, 2019 / CTD Holdings, Inc. (CTDH)("CTD" or the "Company"), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it closed its previously announced private placement of securities with a group of institutional and accredited investors that included directors and officers of the Company. Investors in the private placement purchased a total of 29,770,000 million units, consisting of one share of common stock and one warrant, at a price per unit of $0.25, resulting in gross proceeds of approximately $7.4 million, before deducting placement agent fees and estimated offering expenses.

  • ACCESSWIRE

    CTD Holdings Announces $7.2 Million Private Placement

    ALACHUA, FL / ACCESSWIRE / May 30, 2019 / CTD Holdings, Inc. (CTDH) (''CTD'' or the ''Company''), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announces a private placement to raise approximately $7.2 million. CTD will use the proceeds from the transaction as growth capital and for general corporate purposes. CTD will issue 28,770,000 shares at a price of $0.25 per share and accompanying warrant, resulting in gross proceeds to the Company of $7,192,500, before fees and expenses.

  • ACCESSWIRE

    CTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol (R) Cyclo (TM) for Niemann-Pick Disease Type C

    ALACHUA, FL / ACCESSWIRE / May 23, 2019 / CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced its first home-based infusion of its proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, in a formal clinical trial. "Today's infusion is a milestone for all who have supported CTD's clinical program from the very beginning.

  • ACCESSWIRE

    CTD Announces Participation and Support for Upcoming Gathering of Patient-Support Organizations for Niemann-Pick Disease type C

    ALACHUA, FL / ACCESSWIRE / May 16, 2019 / CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that company representatives will attend and present at the 6th Biennial conference of the International Niemann Pick Disease Alliance (INPDA). The INPDA is a global network of non-profit patient support groups associated with Niemann Pick diseases. Over 40 INPDA members and affiliates from countries around the world, including Australia, China, Norway, France and Brazil, will be represented at the conference, in addition to clinicians, scientists and industry representatives.

  • ACCESSWIRE

    CTD Announces New Expanded Access Program in the United Kingdom using Trappsol(R) Cyclo(TM) Intravenously for Niemann-Pick Disease type C

    ALACHUA, FL / ACCESSWIRE / May 10, 2019 / CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that one patient who completed CTD's Phase I/II clinical trial using the company's proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, will continue to have access to the drug through an approved expanded access program. CTD's Chairman and CEO N. Scott Fine said, "We are pleased to provide continued access to Trappsol® Cyclo™ to this patient. The patient will receive the Trappsol® Cyclo™ intravenously via the Expanded Access program until the Extension Protocol for the Phase I/II trial is fully in place.

  • ACCESSWIRE

    CTD Announces New Expanded Access Program in Taiwan using Trappsol Cyclo for Niemann-Pick Disease type C

    ALACHUA, FL / ACCESSWIRE / May 7, 2019 / CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that two patients from Taiwan who completed CTD's Phase I clinical trial using Trappsol® Cyclo™, the company's proprietary formulation of hydroxypropyl beta cyclodextrin, will continue to have access to the drug through an approved expanded access program in Taiwan. The US trial is "A Phase I Study to Evaluate the Single- and Multiple-Dose Pharmacokinetics of Intravenous Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type C and the Effects of Dosing Upon Biomarkers of NPC Disease" (NCT02939547).

  • ACCESSWIRE

    CTD Holdings Announces M. Flint Beal, MD Joins Scientific Advisory Board

    ALACHUA, FL / ACCESSWIRE / April 15, 2019 / CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with an unmet medical need, today announced that M. Flint Beal, MD will join its Scientific Advisory Board. "Dr. Beal's addition to the Scientific Advisory Board is an important milestone as CTD works to identify new drug development targets and strategies," said N. Scott Fine, CTD's Chairman and CEO.

  • ACCESSWIRE

    CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol (R) Cyclo (TM) in Alzheimer's Disease

    ALACHUA, FL / ACCESSWIRE / March 14, 2019 / CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer's Disease. The trial will use Trappsol® Cyclo™, the company's proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously. ''Alzheimer's Disease is a devastating illness for patients and their families.

  • ACCESSWIRE

    CTD Holdings to Present at Webinar for Patients and Families on Initial Clinical Trial Data

    Webinar Hosted by US Non-Profit Organization Supporting Patients with Niemann-Pick Disease ALACHUA, FL / ACCESSWIRE / March 8, 2019 / CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company ...

  • GlobeNewswire

    CTD Holdings Announces Grant to U.S. Non-Profit Organization to Support Patient Participation in Informational Meetings with Regulators

    CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announces its support for the National Niemann-Pick Disease Foundation (NNPDF), the U.S. national advocacy organization for patients with Niemann-Pick Disease Type C (NPC). The grant from CTD is for $10,000. Funds will be used to support travel costs for patients with NPC and their families to participate in meetings with U.S. regulators as part of increasing efforts for patient participation in drug development conversations.

  • GlobeNewswire

    CTD Announces Appointment of Sharon H. Hrynkow, PhD as Chief Scientific Officer

    CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today the appointment of Sharon H. Hrynkow, PhD, the company’s Senior Vice President for Medical Affairs, as Chief Scientific Officer. Mr. Fine continued, “On behalf of the Board and to our fellow Board member, we are very grateful to Dr. Jeffrey Tate, COO, for his work as CSO over the past years. Dr. Hrynkow, a neuroscientist by training, joined CTD in 2015 to develop the company’s clinical program for Trappsol® Cyclo™, its proprietary formulation of hydroxypropyl beta cyclodextrin used in the treatment of Niemann-Pick Disease Type C (NPC).

  • GlobeNewswire

    CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™ Provided Intravenously for Patients with Niemann-Pick Disease Type C

    CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, reports initial results from its two clinical trials using the company’s proprietary formulation of hydroxypropyl beta cyclodextrins (HPBCDs), Trappsol® Cyclo™, intravenously in patients with Niemann-Pick disease type C. Results were presented at two scientific conferences, WORLDSymposium (We’re Organizing Research on Lysosomal Diseases), held Feb. 4 – 8, 2019, Orlando, Florida and the 13th Annual Brains for Brain (B4B) symposium organized under the auspices of the European Task Force on Brain and Neurodegenerative Lysosomal Storage Diseases, January 24-26, 2019. CTD’s presentations were on February 6 and January 26, respectively.